CareDx price target raised to $26 from $25 at BTIG

BTIG raised the firm’s price target on CareDx (CDNA) to $26 from $25 and keeps a Buy rating on the shares. The company delivered a good Q4 and initiated a 2026 revenue guidance above the Street estimates, albeit the guide was understandably wide in its range, the analyst tells investors in a research note. The firm adds however that while many investors are waiting on the sidelines until a final resolution occurs with CMS, BTIG believes that the stock is cheap regardless of that outcome.